Enalapril prevents fatty liver in nephrotic rats

Journal of Nephrology

Volumn 15, Issue 4, 2002, Pages 358-367

  Toblli, Jorge Eduardo ^a   Ferder, León ^a   Stella, Inés ^a   Angerosa, Margarita ^a   Inserra, Felipe ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

Adriamycin; Enalapril; Fatty liver; Hyperlipidemia; Nephrotic syndrome; Proteinuria

Indexed keywords

ACTIN ANTIBODY; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DRINKING WATER; ENALAPRIL; FAT; LIPID; LIVER ENZYME; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG ACTIVITY; DRUG INDUCED DISEASE; FATTY LIVER; HYPERLIPIDEMIA; INFLAMMATION; INFLAMMATORY INFILTRATE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER CELL; LIVER FUNCTION; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MACROPHAGE; MALE; MONOCYTE; NEPHROTIC SYNDROME; NONHUMAN; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; SCORING SYSTEM; STAINING; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOPSY, NEEDLE; CONFIDENCE INTERVALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENALAPRIL; IMMUNOHISTOCHEMISTRY; MALE; NEPHROTIC SYNDROME; PROBABILITY; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 0036659765     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-83.
2. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences and treatment. Am J Kidney Dis 1994; 23: 331-46.
3. Kark RM. Some remarks on fatty livers and fatty kidneys in the nephrotic syndrome. Scand J Gastroenterol 1970; 7 (suppl): S111-6.
4. Leevy CM. Fatty liver. A study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine 1962; 41: 249-76.
5. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig Dis 1999; 17: 80-9.
6. Ohno T, Horio F, Tanaka S, Tereda M, Namikawa T, Kitoh J. Fatty liver and hyperlipidemia in IDDM (insulin-dependent diabetes mellitus) of streptozotocin-treated shrews. Life Sci 2000; 66: 125-31.
7. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabete Metab 2000; 26: 98-106.
8. Letteron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol 1997; 272: G1141-50.
9. Matsumoto T, Yoshime T, Shimouchi K, Shiotu H, Kuwabara N, Fukuda Y, Hoshi T. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese autopsy register data. Hum Pathol 1992; 23: 1151-8.
10. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-34.
11. O'connor BJ, Kathama B, Tavill AS. Nonalcoholic fatty liver (NASH syndrome). Gastroenterologist 1997; 5: 316-29.
12. Bacon BR, Farahvash MJ, Janney CG, Neushwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
13. Deihl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221-9.
14. Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J. ACE inhibitors and AT1 receptor antagonists, beyond the haemodynamic effect. Nephrol Dial Transplant 2000; 15: 561-5.
15. Suzuki Y, Ruiz-Ortega M, Egido J. Angiotensin II: a double-edged sword in inflammation. J Nephrol 2000; 13 (suppl 3): S101-10.
16. Anthuber M, Farkas S, Rihl M, Menger MD, Schildberg FW, Jauch KW, Messmer K. Angiotensin-converting enzyme inhibition by enalapril: A novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation. Hepatology 1997; 25: 648-51.
17. Gajdos M, Krivosikova Z, Sebekova K, Lajdova I, Spustova V, Dzurik R. Enalapril inhibits growth and proliferation of various tissue in rat normotensive four-sixths kidney ablation nephropathy. Kidney Blood Press Res 2000; 23: 106-12.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC an unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
19. Reeves HL, Alastair BD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25: 677-83.
20. Joven J, Espinel E, Simo JM, Vilella E, Camps J, Oliver A. The influence of hypoalbuminemia in the generation of hyperlipidemia. Atherosclerosis 1996; 126: 243-52.
21. Kaysen GA, de Sain-van der Valden MG. New insights into lipid metabolism in the nephrotic syndrome. Kidney Int 1999; 55 (suppl 71): S18-21.
22. Lu L, Zeng M. Li J, Hua J, Fan J, Fan Z, Qiu D, Xiao S. Effects of Kupffer cells stimulated by triglyceride and very low-density lipoprotein on proliferation of rat hepatic stellate cells. Chin Med J (Engl) 1999; 112: 325-9.
23. Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 1995; 22: 28-36.
24. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19: 129-40.
25. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
26. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-66.
27. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998; 18: 2-13.
28. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor beta-1 expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7.
29. Klahr S, Morrisey JJ. Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998; 31: 171-6.
30. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
31. Toblli JE, Stella I, De Cavanagh EM, Angerosa M, Inserra F, Ferder L. Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Hypertension 1999; 33 (part II): 225-31.
32. Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F. Protective role of enalapril for for chronic tubulointerstitial lesions of hyperoxaluria. J Urol 2001; 166: 275-80.
33. Inserra F, Romano L, de Cavanagh EM, Ercole L, Ferder LF, Gomez RA. Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. J Am Soc Nephrol 1996; 7: 676-80.
34. Morrisey JJ, Ishidoya S, McCracken R, Klahr S: Nitric oxide generation ameliorates the tubulointerstial fibrosis of obstructive nephropathy. J Am Soc Nephrol 1996; 7: 2202-12.
35. Inserra F, Paglia N, Stella I, Toblli JE, Gimenez M, Ferder L, Basso N. Protective effects of enalapril on hepatic fatty changes and lipids levels in normal adult and aging rats (Abstract). 18th Scientific Meeting of the International Society of Hypertension, Chicago USA, 2000. J Hypertens 2000; 18 (suppl): S158.
36. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274: F580-6.
37. Day CP, James OF. Hepatic steatosis: Innocent bystander or guilty party? Hepatology 1998; 27: 1463-6.
38. de Cavanagh EM, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG. Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett 1995; 361: 22-4.
39. de Cavanagh EM, Fraga CG, Ferder LF, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissue. Am J Physiol 1997; 272: R514-8.
40. de Cavanagh EM, Inserra F, Ferder L, Fraga CG. Enalapril and captopril enhance glutathion-dependent antioxidant defenses in mouse tissue. Am J Physiol 2000; 278: R572-7.
41. de Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG, Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001; 38: 1130-6